Table 2.
Multivariable Survival Analysis of IPF Patients Across All Three Cohorts
| Dallas IPF cohort | Chicago IPF cohort | San Francisco IPF cohort | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Hazard Ratio (95% CI) | P-value | Hazard Ratio (95% CI) | P-value | Hazard Ratio (95% CI) | P-value | |
| Multivariable analysis (individual covariates) | (n=135) | (n=123) | (n=49) | |||
|
| ||||||
| Age | 1·02 (0·99 – 1·04) | 0·26 | 0·99 (0·96 – 1·03) | 0·66 | 1·02 (0·98 – 1·07) | 0·36 |
| Male Sex | 1·3 (0·78 – 2·14) | 0·31 | 2·24 (0·89 – 5·68) | 0·088 | 1·33 (0·38 – 4·62) | 0·65 |
| FVC, % predicted | 0·81 (0·67 – 0·97) | 0·023 | 0·91 (0·70 – 1·17) | 0·45 | 0·85 (0·64 – 1·15) | 0·30 |
| DLCO, % predicted | 0·72 (0·58 – 0·89) | 0·0021 | 0·60 (0·47 – 0·78) | 0·00013 | 0·77 (0·57 – 1·05) | 0·097 |
| Telomere Length | 0·22 (0·08 – 0·63) | 0·0048 | 0·11 (0·03 – 0·39) | 0·00066 | 0·25 (0·07 – 0·87) | 0·029 |
|
| ||||||
| Multivariable analysis (GAP score) | (n=143) | (n=124) | (n=50) | |||
|
| ||||||
| GAP score | 2·62 (1·79 – 3·84) | <0·0001 | 3·67 (1·94 – 6·95) | <0·0001 | 2·81 (1·35 – 5·87) | 0·0058 |
| Telomere length | 0·5 (0·20 – 1·26) | 0·14 | 0·21 (0·06 – 0·76) | 0·018 | 0·25 (0·08 – 0·84) | 0·024 |
The reported hazard ratios are per a 10% difference in FVC and DLCO measurements and per a 1-unit difference in log T/S ratios. Patients who were unable to perform the DLCO test (n=9 in the Dallas cohort, n=1 in the Chicago cohort, and n=1 in the San Francisco cohort) were excluded from analysis when using individual covariates, but included when using GAP score.